Shionogi &Shionogi & Co.,Ltd.4507東証プライム医薬品FY ending Mar 2024, consolidated, IFRS
Shionogi & brought in ¥335.1B in revenue.
Revenue changed -8.9% from the prior year.
FY ending Mar 2019 → FY ending Mar 2022
FY ending Mar 2019 → FY ending Mar 2022
※ Cost of revenue is not disclosed; expenses are combined
※ Operating income is not disclosed; the chart goes straight to pretax income including investment gains
A machine-readable operating income value exists, but it is not in the validated published data, so the chart is omitted.
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.